{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062903","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.580698+00:00","generated_at":"2026-06-08T05:21:32.502345+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ALX Oncology Q3 net loss $51.0M; positive Phase 2 gastric cancer data; CEO change","bullets":["Q3 2023 GAAP net loss $51.0M ($1.24/diluted share) vs $35.3M ($0.87) in Q3 2022.","Cash, equivalents and investments $196.4M; runway into early 2026 including recent $63.2M offering proceeds.","Interim Phase 2 ASPEN-06: confirmed ORR 52% for evorpacept combo arm vs 22% for control in HER2+ gastric/GEJ cancer.","Leadership realignment: Jason Lettmann appointed CEO, Jaume Pons becomes President and CSO.","Closed public offering of common stock and pre-funded warrants in Oct 2023 for gross proceeds ~$63.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062903","json":"https://secwatch.observer/filing/0000950170-23-062903.json","markdown":"https://secwatch.observer/filing/0000950170-23-062903.md","text":"https://secwatch.observer/filing/0000950170-23-062903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023062903/0000950170-23-062903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023062903/alxo-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:21:32.502345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d243c04e0da1482f51726fc2622e150f6b4b494","claim":"ALX ONCOLOGY HOLDINGS INC reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, ALX Oncology Holdings Inc. (the \"Company\"), issued a press release announcing its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023062903/0000950170-23-062903-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}